Delaware Court Ruling Sends GSK Shares into Freefall Over Zantac Controversy
Monday, 3 June 2024, 07:52
GSK shares hit hard
Ruling from the Delaware court has caused a sharp decline in GSK's stock, impacted by legal concerns surrounding Zantac.
Zantac fallout
Plaintiffs now allowed to present evidence linking the heartburn drug to cancer risks, further jeopardizing GSK's position in the market.
- Major blow to GSK's reputation.
- Increased vulnerability amidst mounting legal battles.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.